MediciNova (MediciNova) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2006. Start your Free Trial

What is MediciNova FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. MediciNova's Free Cash Flow for the three months ended in Dec. 2023 was $-0.50 Mil. MediciNova's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, MediciNova's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, MediciNova's current FCF Yield % is -11.57%.

The historical rank and industry rank for MediciNova's FCF Margin % or its related term are showing as below:

MNOV' s FCF Margin % Range Over the Past 10 Years
Min: -745.2 Med: -489.13 Max: -233.06
Current: -743.1

During the past 13 years, the highest FCF Margin % of MediciNova was -233.06%. The lowest was -745.20%. And the median was -489.13%.

MNOV's FCF Margin % is ranked worse than
71.76% of 1034 companies
in the Biotechnology industry
Industry Median: -148.935 vs MNOV: -743.10

MediciNova FCF Margin % Historical Data

The historical data trend for MediciNova's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MediciNova FCF Margin % Chart

MediciNova Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-233.06

-745.20

MediciNova Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-137.20	-

Competitive Comparison of MediciNova's FCF Margin %

For the Biotechnology subindustry, MediciNova's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MediciNova's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MediciNova's FCF Margin % distribution charts can be found below:

* The bar in red indicates where MediciNova's FCF Margin % falls into.

MediciNova FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

MediciNova's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-7.452	/	1
	=	-745.20 %

MediciNova's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-0.499	/	0
	=	%

MediciNova FCF Margin % Related Terms

Thank you for viewing the detailed overview of MediciNova's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

MediciNova (MediciNova) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MediciNova Inc (NAS:MNOV) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

4875:Japan

Address

4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037

Website

https://www.medicinova.com

MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.

Executives

Nicole Lemerond	director	3 MURRAY HILL ROAD, SCARSDALE NY 10583
Hideki Nagao	director	4350 LA JOLLA VILLAGE DRIVE, SUITE 950, SAN DIEGO CA 92122
Jason J Kruger	officer: Chief Financial Officer	4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Douglas Paulin	officer: Chief Financial Officer	4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Gaeta Federico C.a.	officer: Chief Scientific Officer	4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
3d Investment Partners Pte. Ltd.	10 percent owner	250 NORTH BRIDGE ROAD, #13-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
3d Opportunity Master Fund	10 percent owner	C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Carolyn Beaver	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Stepanow Edward C Jr.	officer: Chief Financial Officer	4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA 92037
Kazuko Matsuda	officer: Chief Medical Officer	C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yuichi Iwaki	director	C/O MEDICINOVA, INC., 4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Carla Reyes	officer: Chief Financial Officer	4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA CA 92037
Yoshio Ishizaka	director	4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Yutaka Kobayashi	director	4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037
Geoffrey Obrien	officer: Vice President	4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA CA 92037